Premium
Altered expression of syndecan‐1 in prostate cancer
Author(s) -
KIVINIEMI JOHANNA,
KALLAJOKI MARKKU,
KUJALA IINA,
MATIKAINEN MARJATERTTU,
ALANEN KALLE,
JALKANEN MARKKU,
SALMIVIRTA MARKKU
Publication year - 2004
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2004.apm1120202.x
Subject(s) - syndecan 1 , prostate cancer , cancer , prostate , cancer research , immunohistochemistry , biology , extracellular matrix , pathology , du145 , cancer cell , cell , medicine , microbiology and biotechnology , lncap , biochemistry
Syndecan‐1 is a cell surface heparan sulfate proteoglycan expressed by epithelial cells. It interacts with growth factors, matrix components, and other extracellular proteins, and is thought to be involved in processes such as cell growth, differentiation and adhesion. The expression of syndecan‐1 appears generally downregulated in human carcinomas and in experimental cancer models, whereas transfectional expression of syndecan‐1 in cultured cancer cells has been shown to inhibit their growth and other aspects of malignant behavior. These findings suggest that analysis of syndecan‐1 expression might be of prognostic value in cancer diagnosis, and studies on some carcinomas indeed point to an inverse correlation between syndecan‐1 expression and cancer prognosis. So far, little information has been available on the expression of syndecan‐1 in human prostate and prostate disease. We have generated and characterized novel antibodies against syndecan‐1 and applied them to immunohistochemical staining of specimens representing normal prostate as well as benign and malignant (n=23) prostate disease. The results indicate that syndecan‐1 expression is altered but not uniformly absent in prostate cancer, which is in contrast to the expression of high‐molecular‐weight cytokeratins. The data initially suggest an inverse correlation between syndecan‐1 expression and Gleason grade of the tumor, and warrant a larger study to assess the potential prognostic value of analysing syndecan‐1 expression in prostate carcinoma.